Novo Nordisk A/S (NVO)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $183.52B
Last updated: Nov 17, 2026 at 5:28 PM ET
Novo Nordisk A/S (NVO) Stock Chart
Novo Nordisk A/S (NVO) has a latest price of $40.70 on Nov 17, 2026, 33.4% below its 52-week high of $61.11. Its price fell 12.7% over the past 12 months. The month-end price rose 125.1% over the 10 years through Oct 2026, a compound annual rate of 8.5%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $142.74 in Jun 2024 and its lowest $16.80 in Nov 2016, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart NVO with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for NVO.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 12.4%, and over 6 months it fell 6.9%. The month-end price fell 58.6% over the 3 years through Oct 2026, a compound annual decline of 25.5%.
| Period | Change |
|---|---|
| 1 month | +5.9% |
| 3 months | -12.4% |
| 6 months | -6.9% |
| 12 months | -12.7% |
| 12 months, with dividends | -8.9% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -58.6% | -25.5% |
| 5 years | -27.4% | -6.2% |
| 10 years | +125.1% | +8.5% |
Price by Year
Its best calendar year was 2021, when the price rose 60.3%, and its weakest was 2025, when it fell 40.9%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $40.00 | -21.4% |
| 2025 | $50.88 | -40.9% |
| 2024 | $86.02 | -16.8% |
| 2023 | $103.45 | +52.9% |
| 2022 | $67.67 | +20.8% |
| 2021 | $56.00 | +60.3% |
| 2020 | $34.92 | +20.7% |
| 2019 | $28.94 | +25.6% |
| 2018 | $23.04 | -14.2% |
| 2017 | $26.84 | +49.7% |
Trading Range
The price is 2.0% above its 50-day average of $39.90 and 4.1% below its 200-day average of $42.46.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $40.70 | |
| 52-week high | $61.11 | -33.4% |
| 52-week low | $34.15 | +19.2% |
| 50-day average | $39.90 | +2.0% |
| 200-day average | $42.46 | -4.1% |
Price Risk
Over 3 years, its largest fall from a peak was 75.0%.
| Measure | Value |
|---|---|
| 1-year beta | 0.95 |
| Largest fall, 1 year | -44.4% |
| Largest fall, 3 years | -75.0% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About NVO
What is NVO's 1-year price change?
Novo Nordisk A/S's price fell 12.7% over the past 12 months. With dividends included, the 12-month total return was -8.9%.
What is NVO's 5-year price change?
Novo Nordisk A/S's month-end price fell 27.4% over the 5 years through Oct 2026, a compound annual decline of 6.2%. These figures leave out dividends.
What is NVO's 52-week high and low?
Novo Nordisk A/S's 52-week high is $61.11 and its 52-week low is $34.15. Its latest price of $40.70 on Nov 17, 2026 is 33.4% below the high.
What is NVO's beta?
Novo Nordisk A/S's 1-year beta against the S&P 500 is 0.95, so its price has moved about in line with the market over the past year. Its largest fall from a peak over the past year was 44.4%.
Is the NVO chart free?
Yes. Advanced Charting for NVO is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
NVO pages: Overview, Dividends, Charting, Financials, Statistics, Valuation, Competitors